Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 88 | 0.91 |
| pathways Reactome | Reactome did not answer (Reactome: HTTP 429) | 0.00 |
No case: the score is under the bar. Receipt 9128
Sealed predictions
- FAM111A in dopamine neurons, braak-0.36 (p 0.347) → +0.33 (p 0.387)receipt 9135
Swarm cases
receipt 9135: FAM111A in dopamine neurons, braak
- power
- full sample -0.03 (p 0.922, n 18), 95% CI -0.49 to +0.45. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.04 (p 0.881, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.01 (p 0.962, n 18). could be the mix.
- skeptic
- leave-one-out range -0.15 to +0.09, sign flips 7; without severely affected donors -0.03 (p 0.922, n 18). fragile.
- cell type
- strongest in OPCs: +0.65 (p 0.0037, n 18) vs -0.03 in dopamine neurons. proposing OPCs.
- axis
- no measure beats "tracks Braak Lewy-body stage" for FAM111A in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up FAM111A · OPCs · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.10 p 0.722 (needs p < 2.3e-4)
Receipts
loading the receipts